Consensus conference: Implementing treatment recommendations on yttrium-90 immunotherapy in clinical practice – Report of a European workshop

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group

W. Hiddemann · Blood · 2005 · 1.3K citations · Full text

Medicine, Oncology, Pharmacotherapy +7

Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma

Thomas E. Witzig, Leo I. Gordon, Fernando Cabanillas et al. · Journal of Clinical Oncology · 2002 · 1.2K citations

Medicine, Immunology, Oncology +14

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma

R. E. Marcus · Blood · 2004 · 970 citations · Full text

Medicine, Oncology, Pharmacotherapy +5

¹³¹I-Tositumomab Therapy as Initial Treatment for Follicular Lymphoma

Mark Kaminski, Melissa Tuck, Judith Estes et al. · New England Journal of Medicine · 2005 · 715 citations · Full text

Medicine, Hematology, Oncology +15

Treatment With Ibritumomab Tiuxetan Radioimmunotherapy in Patients With Rituximab-Refractory Follicular Non-Hodgkin’s Lymphoma

Thomas E. Witzig, Ian W. Flinn, Leo I. Gordon et al. · Journal of Clinical Oncology · 2002 · 650 citations

Medicine, Hematology, Pharmacotherapy +14